secwatch.observer — SEC 8-K summary
======================================

Issuer:     ROCKET PHARMACEUTICALS, INC. (RCKT)
CIK:        0001281895
Form:       8-K
Filed at:   2026-08-27T20:06:27+00:00
Accession:  0001140361-26-034689
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Rocket Pharma adopts severance program; new CEO/GC/COO employment agreements
----------------------------------------------------------------------------

- CEO Gaurav Shah gets $674,856 base salary, 60% target bonus; 15-month severance (non-CIC) and 18-month (CIC).
- GC Martin Wilson gets $547,313 base salary, 45% target bonus; 12-month severance, plus 12-month CIC terms.
- COO Christopher Stevens amendment: 12-month base salary severance, CIC terms include target bonus and prorated bonus.
- New severance program covers all eligible US employees; CEO gets 15/18 months, ELT 12 months, VPs 6/9 months, etc.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1281895/000114036126034689/0001140361-26-034689-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1281895/000114036126034689/ef20081170_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-034689

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer